infused into the rat frontoparietal cortex using an osmotic minipump.
One week later, rats were subcutaneously administered PCA (10 mg/kg) or vehicle, and the 5-HT innervation was evaluated after two more weeks of neurotrophin infusion.
As revealed with 5-HT immunocytochemistry, BDNF infusions into the neocortex of intact (non-PCA-lesioned) rats caused a substantial increase in 5-HT axon density in a 3 mm diameter region surrounding the cannula tip. In PCA-lesioned rats, intracortical infusions of BDNF completely prevented the severe neurotoxin-induced loss of 5-HT axons near the infusion cannula. In contrast, cortical infusions of vehicle or the control protein cytochrome c did not alter the density of serotonergic axons in intact animals, nor did control infusions prevent the loss of 5-HT axons in PCA-treated rats. NT-3 caused only a modest sparing of the 5-HI innervation in PCA-treated rats, and NGF failed to prevent the loss of 5-HT axon density. The immunocytochemical data were supported by neurochemical evaluations which showed that BDNF attenuated the PCA-induced loss of 5-HT and 5-HIAA contents Recei ved Jan. 24, 1995; revised July 25, 1995; accepted Aug. 4, 1995 Extensive research in recent years has shown that small proteins called neurotrophins have profound influences upon the development, survival, regulation of function, and plasticity of diverse neuronal populations in both the CNS and PNS (reviewed by Levi-Montalcini, 1987; Lindsay et al., 1994) . The neurotrophins comprise a family of homologous proteins which includes nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/S (NT-46). Despite the 50-5.5s similarity in the amino acid composition of these molecules (Hohn et al., 1990; Maisonpierre et al., 1990) , the different neurotrophins promote the survival of distinct, yet overlapping, sets of central and peripheral neurons. For example, sympathetic neurons respond to NGF and NT-3 but not to BDNF (Maisonpierre et al., 1990; Rosenthal et al., 1990) , while cultured mesencephalic dopamine neurons respond to BDNF and NT-3 but not to NGF . On the other hand, both NGF and BDNF support the survival and differentiation of cholinergic neurons in the basal forebrain (Alderson et al., 1990; Kntisel et al., 1991) . Because the neurotrophins can prevent the degeneration or facilitate recovery of injured neurons in the adult nervous system, these factors have been proposed as potential therapeutic agents for treating the structural deteri'oration of neurons that occurs during aging or in neurodegenerative diseases (reviewed by Hefti et al., 1989; Gage et al., 1990; Lindsay et al., 1994 ). An impaired function of brain serotonergic (5HT) systems has been implicated in a number of neurologic disturbances including the major depressive disorders, anxiety, obsessive-compulsive behavior, migraine, and obesity (Whitaker- Azmitia and Peroutka, 1990) . Furthermore, the recreationally abused drugs methamphetamine, 3$methylenedioxyamphetamine (MDA) and 3&methylenedioxymethamphetamine (MDMA) and the clinically prescribed anorectic agent fenfluramine cause an extensive degeneration of serotonergic axons in laboratory animals, including nonhuman primates (reviewed by . A recent study by ) were continously infused into the right frontoparietal cortex over a 3 week period via a cannula connected to an osmotic minipump. One week after the start of the intracortical infusion, rats were administered one subcutaneous injection of either PCA (10 mg/kg) or saline vehicle. Two weeks after PCA (or vehicle) administration, rats were sacrificed and the brains prepared for immunocytochemical staining of 5-HT neurons or neurochemical measurements of 5HT and 5-HIAA levels and high-affinity 'H-5-HT uptake.
found in aged rats (van Luijtelaar et al., 1992) and in human age-related neurodegenerative disorders. On a par with cholinergic neuron loss, there is a profound loss of 5-HT neurons and their processes in Alzheimer's disease (Cross, 1990) , and 5-HT neurons are extensively depleted in Parkinson's disease (Agid et al., 1992) . Despite the clinical importance of serotonin, very little is known about the endogenous factors that have neurotrophic influences upon serotonergic neurons. In vitro experiments have shown that the astrocyte-derived protein S-1 OOP enhances the neurite outgrowth, but not survival, of serotonergic neurons in embryonic raphe cultures Liu and Lauder, 1992) . A soluble, but unidentified, factor extracted from the 5-HT denervated hippocampus can markedly enhance the survival and sprouting of grafted serotonergic neurons in the cerebellum (Zou and . These findings suggest the existence in brain of an endogenous survival factor for serotonergic neurons. Several recent in vivo studies suggest that some members of the neurotrophin family have functional influences upon serotonergic neurons in the brain. High-affinity binding sites for Iz51-NT-3 and mRNA transcripts for trkB and trkC, the signal-transducing receptors for BDNF and NT-3, respectively (Merlio et al., 1992) are found in the dorsal raphe nucleus. Moreover, BDNF is retrogradely transported from 5-HT terminal fields in the striatum and hippocampus to cell bodies in the raphe nuclei (Anderson et al., 1995) . Finally, BDNP and to a lesser extent NT-3, greatly augment 5-HT metabolism and potentiate 5-HT-related behaviors when chronically infused into the substantia nigra Martin-Iverson et al., 1994) or in the midbrain region near the dorsal raphe and periaqueductal gray (Siuciak et al., 1994) . Presently, it is not known whether the neurotrophins can protect serotonergic neurons from injury or induce the sprouting of 5-HT axons in the brain.
The present study examined whether BDNE NT-3, or NGF could protect serotonergic neurons in the adult rat brain from chemical axotomy. Normally, serotonergic axons densely innervate most areas of the brain and spinal cord, and arise almost exclusively from cell bodies located in the raphe nuclei of the brainstem (reviewed by Molliver, 1987) . Systemic administration of the selective 5-HT neurotoxin p-chloroamphetamine (PCA), or other neurotoxic amphetamine derivatives such as MDA, MDMA, or fenfluramine, cause a rapid degeneration of most serotonergic axon terminals in the forebrain, while sparing 5-HT cell bodies in the raphe nuclei and preterminal fibers (Mamounas and O'Hearn et al., 1988; Appel et al., 1989; Mamounas et al., 1991; Axt et al., 1992) . This pruning of 5-HT axon terminals while sparing their cell bodies leads to a slow, progressive sprouting response from the damaged 5-HT axons in cortex that begins about 1-2 months after PCA treatment (Mamounas et al., 1992; Axt et al., 1994) . In the present study, we assessed whether continuous infusion of BDNF, NT-3, or NGF into rat frontoparietal cortex could prevent the severe loss of serotonergic axons that is normally observed 2 weeks after systemic administration of PCA.
Materials and Methods
Experimental paradigm. Adult male, Sprague-Dawley rats (200-220 gm at the start of the experiment; II = 4-14/group) were housed and treated in compliance with AALAC guidelines. Recombinant human BDNF (2 pg/pl; 12 kg/d), NT-3 (2 p,g/pl; 12 kg/d) or NGF (0.9 pg/ pl; 5.4 pg/d), or the control substances insect cytochrome c (2 pg/pl; 12 pg/d) or vehicle (sterile PBS) were continously infused into the right neocortex over a 3 week period via a cannula connected to an osmotic minipump (Fig. 1) . One week after the start of the intracortical infusion, rats were administered one subcutaneous injection of either d-l, PCA (10 mg/kg, expressed as the free base; Sigma Chemical Corp., St. Louis, MO) or vehicle (isotonic saline), as described (Mamounas et al., 1991) . Two weeks after PCA (or vehicle) administration, rats were sacrificed and the brains prepared for immunocytochemical staining of 5-HT neurons or neurochemical measurements of 5HT and 5-hydroxyindole acetic acid (5-HIAA) levels and high-affinity ?H-5-HT uptake. For each animal, the contralateral, noninfused (left) cortex served as an internal control for the extent of 5-HT denervation caused by systemically administered PCA, whereas the ipsilateral (right) cortex infused with vehicle or cytochrome c served as a between group control for infusion.
Abbreviations usedfor the treatment groups. The chronic intracortical infusion of the control substances cytochrbme c or PBS produced similar results regarding 5-HT immunocytochemical staining and neurochemical measurements in both intact and PCA-lesioned rats. Therefore, we have assigned the following abbreviations to the different treatment groups employed in this study: veWveh animals received a unilateral, intracortical infusion of PBS or cytochrome c for 3 weeks followed, 1 week after the start of the infusion, by a subcutaneous injection of saline; veh/PCA animals were infused intracortically with PBS or cytochrome c followed by subcutaneous administration of PCA; BDNF/ veh animals were infused intracortically with BDNF followed by a subcutaneous injection of saline; BDNF/PCA animals were infused intracortically with BDNF followed by a subcutaneous injection of PCA; NGF/PCA animals received a unilateral, intracortical infusion of NGF followed by subcutaneous administration of PCA; NT-3/PCA animals received a unilateral intracortical infusion of NT-3 followed by a subcutaneous injection of PCA.
Animal surgery. Alzet 2002 osmotic minipumps (Alza Corp., Palo Alto, CA) were coated 50% with dental wax to lower the nominal flow rate of 0.5 pl/hr to approximately 0.25 pl/hr. The pump was attached of Neuroscience, December 1995, 15(12) 7931 to a 2 cm piece of silated PE50 tubing (Micro-Renathane; Braintree Scientific, Braintree, MA) and connected to a 1.6 mm long, 28 G stainless steel cannula (Plastics One, Roanoke, VA). The pumps and flow moderators were filled with PBS or with cytochrome c, recombinant human BDNF, NGF, or NT-3 at concentrations of 0.90 mg/ml (NGF) or 2.0 mg/ml (all others substances). The lower concentration of NGF was used because of its superior delivery properties and higher affinity for binding to brain compared with BDNF or NT-3. Each rat was anesthetized with an intraperitoneal injection of 149 mg/kg chlorohydrate and 30.8 mg/kg sodium pentobarbital and mounted in a small animal stereotaxic apparatus (David Kopf Instruments, Tijunga, CA). A 2 cm midline incision was made on the scalp, through which the osmotic pump was inserted and implanted in a subcutaneous pocket between the shoulder blades. The cannula was positioned in the right frontoparietal cortex using the following stereotaxic coordinates: 1.8 mm anterior and 2.0 mm lateral to bregma, and 1.6 mm below the skull surface. The cannula was inserted through a 0.5 mm hole drilled at this location and was glued flush to the skull with cyanoacrylate adhesive. The scalp incision was closed with wound clips. 5-HT and BDNF immunocvtochemistrv. Animals were deeply anesthetized with chloral hydrate (400 mglkg,.i.p.) and perfused th;o;gh the aorta with cold PBS (DH 7.4) followed bv 4% oaraformaldehvde in 0.15 M phosphate buffer (;H 7.4j. Brains weie postfixed for 4-6'hr at 4"C, and then cyroprotected in 20-30% sucrose (4°C) for 3 d. Coronal sections through the cannula site were cut frozen at 30 Frn on a sliding microtome. Free-floating sections were incubated in antiserum directed against 5-HT (Incstar Corp., Stillwater, MN), diluted 1: 15,000 (Mamounas et al., 1991) . To assess the intracerebral distribution of the infused BDNE adjacent sections were incubated with a turkey anti-BDNF antibody (Amgen, Inc.) at a dilution of 1:7,500 (Morse et al., 1993) . Bound immunoglobulin was visualized with the avidin-biotin-peroxidase method (Vector Laboratories, Burlingame, CA), using diaminobenzidine tetrachloride as the substrate. Staining of 5-HT axons in cortex was not observed when the primary or secondary antibodies were omitted from the respective incubation mixtures.
Indoleamine concentrations and high afinity 5-HT uptake. Each brain was rapidly excised and placed on an ice-chilled metal block. A 3.0 mm OD diameter stainless steel tube (approx. 2.5 mm ID) was centered over the cortical region of cannula penetration and lowered through the cortex. The tube was removed and the cylinder of cortical tissue was excised by separating it from the dorsal surface of the corpus callosum. Other cortical cylinders were similarly prepared in the contralateral frontoparietal cortex and bilaterally in the occipital cortex. The cortical cylinders were weighed and homogenized in 200 ~1 of 0.32 M sucrose. One 45 p,l aliquot of this homogenate was immediately acidified and assayed for 5-HT and 5-HIAA contents by HPLC with electrochemical detection, using the ESA 16 channel coulometric array detector system (CEAS 5300; ESA, Inc,, Bedford, MA; Gamache et al., 1993) . Other 10 ~1 aliquots of the tissue homogenate were immediately assayed for ?H-5-HT uptake in Krebs-Ringer solution containing 10 FM pargyline and 20 nm 'H-5-HT (total volume 200 ~1). Samples were vortexed, incubated for 10 min at 37"C, and rapidly filtered three times with cold buffer. Nonspecific uptake was defined by the addition of 10 PM clomipramine to the buffer while incubating at 0°C. For studies examining the in vitro effects of BDNF (or NT-3) on 'H-5-HT uptake into the neocortex of untreated animals, 10 ~1 of BDNF was added to both total and nonspecific samples for a final concentration of BDNF ranging from 20 PM to 2 FM. Protein determinations were carried out using the BCA protein kit (Pierce, Rockford, IL).
Statistical analysis. The statistical significance of changes in neurochemical measurements was assessed with a 2 X 2 X 2 (PCA treatment X BDNF infusion X side of cortex) analysis of variance (ANOVA) with repeated measures on side of cortex. In the case of significant main effects or interactions, post hoc comparisons were performed using the Newman-Keuls multiple range test. To minimize the between-animal variability in the magnitude of the PCA lesion, the data were also analyzed b$ calculating the ratio of the neurochemical measure (5-HT or 5-HIAA concentration or 3H-5-HT uotake) in the infused (right', cortex relative to the contralateral (noninfised) 'cortex for each 'aI%al. The ratio data were analyzed with a 2 X 2 (PCA treatment X BDNF infusion) ANOVA, followed by the Newman-Keuls multiple range test.
Results

5-HT immunocytochemistry
Intrucortical infusions of vehicle in intact and PCA-treated animals. In control rats (veh/veh; see Materials and Methods section for abbreviations and Fig. 1 , for experimental design), there was a high density of 5-HT-immunoreactive axons throughout cortex (Figs. 2, 3: veh/veh) , as previously observed in intact, non PCA-lesioned rats (Blue et al., 1988; Mamounas et al., 1991) . Three week infusions of cytochrome c (n = 4) or PBS (n = 5) into frontoparietal cortex of intact rats (veh/veh) produced a small zone (0.1-0.2 mm) of nonspecific tissue necrosis immediately adjacent to the cannula site, but there was no change in the density or morphology of 5-HT-immunoreactive fibers in the region surrounding the cannula or elsewhere in cortex (Fig. 2) . Subcutaneous administration of PCA to rats with intracortical infusions of cytochrome c or PBS (veWPCA) caused a dramatic loss of 5-HT axon density throughout cortex, similar to that obtained with PCA treatment alone Mamounas et al., 1991) . Infusions of cytochrome c (n = 7) or PBS (n = 7) into neocortex had minimal effects upon the severe PCA-induced denervation (Fig. 2) . Although a few 5-HT fibers were sometimes found immediately adjacent to the cannula tract, there was still a dramatic loss of 5-HT axon density in the cortical area near the infusion cannula and elsewhere in cortex of veh/PCA animals.
The neurotrophic e#&s of BDNF upon .5-HT axons in intuct and PCA-treated animals. Despite the normally high serotonergic innervation density in the intact cortex, a 3 week intracortical infusion of BDNF in the BDNF/veh animals caused a substantial increase in 5-HT axon density in an approximately 3 mm diameter region surrounding the tip of the infusion cannula (Figs.  2, 3) . A marked increase in 5-HT axon density was seen in each of the six BDNF/veh animals when compared to control (veW veh) animals. Interestingly, the higher axon density was often localized within an approximately 0.5-I mm wide annular rim, beginning 0.5-l mm from the tip of the BDNF infusion cannula (Fig. 2) . Infusion of BDNF into the neocortex of PCA-lesioned rats (BDNF/PCA) prevented the severe neurotoxin-induced loss of serotonergic axons in an approximately 3 mm diameter region surrounding the tip of the BDNF infusion cannula (Fig. 2) . Cortical areas more distant than about 2 mm from the BDNF infusion site, and the contralateral cortex, were nearly devoid of 5-HT axons in the BDNF/PCA rats. In each of the fourteen BDNF/PCA animals, the 5-HT axon density near the BDNF infusion cannula appeared to be markedly higher than what was found in the veh/PCA control animals. As in the BDNF/veh animals, there was often an annulus of extremely high 5-HT axon density in the BDNF/PCA animals, beginning about 0.5-l mm from the BDNF infusion site (Fig. 2) . In many cases, the density of 5-HT axons within this annulus appeared to be even higher than the serotonergic innervation density found in the vehicle infused cortex of intact (vehlveh) animals (Figs. 3, 4) . The spatial distribution of the spared serotonergic axons surrounding the BDNF infusion cannula corresponded closely with the area of diffusion of the infused BDNF, as revealed in an adjacent section immunostained with an antibody against recombinant human BDNF (Fig. 5) . In both BDNF/veh and BDNF/PCA rats, the morphology of the serotonergic axons near the BDNF infusion cannula resembled 5-HT axon terminals in that most of these fibers were fine with numerous closely spaced, small varicosities (cf., Mamounas et al., 1991) . However, the BDNF-exposed 5-HT axons appeared to be slightly thicker, more intensely immunoreactive and more convoluted than those in the homologous cortex of veh/veh animals (Fig. 4) .
The effects of NGF and NT-3 on 5-HT axons in PCA-treated ruts. Unlike BDNF, infusions of NGF into the neocortex of PCA-lesioned rats (NGF/PCA; n = 5) failed to prevent the loss vation density in an approximately 3 mm diameter region surof 5-HT axon density (Fig. 2) . The cortical area near the NGF rounding the infusion cannula (Fig. 2) . However, NT-3 was infusion site was nearly devoid of serotonergic axons, similar to much less effective than BDNF in preventing the PCA-induced what was seen with vehicle infusions in PCA-treated rats (vet?/ loss of serotonergic axons. Moreover, the dense annulus of 5-HT PCA). Intracortical infusions of NT-3 in PCA-lesioned rats (NTaxon sparing found in the BDNF/PCA animals was not found in 3/PCA; n = 4) produced a modest sparing of the 5-HT innerthe NT-3/PCA animals. Figure 3 . Serotonergic axons near the infusion cannula in rat frontoparietal cortex. Higher magnification dark-field photomicrographs of the "annulus" of higher 5-HT axon density (see Fig. 2 ; cannula tract is to the right and out of the field of view of each photograph). There is a high density of 5-HT-immunoreactive axons in the vehicle infused cortex of intact rats (veWveh), but note the supranormal densities of 5-HT axons in the BDNF infused cortex of both PCA-lesioned (BDNFPCA) and intact (BDNF/veh) animals. Scale bar, 100 pm.
In vivo neurochemical evaluations 5-HT and .5-HIAA measurements. Three week intracortical infusions of vehicle did not alter indoleamine concentrations in intact animals: vehlveh animals had similar levels of 5-HT and its metabolite 5-hydroxyindole acetic acid (5-HIAA) in the vehicle infused (right) and contralateral, noninfused (left) frontoparietal cortices (Table 1 ; three-factor repeated measures ANO-VA, followed by the Newman-Keuls multiple range test, p 2 0.05). Subcutaneous administration of PCA caused a significant reduction in cortical levels of 5-HT (. Table 1 ; main effect of PCA treatment: F,,z, = 128, p < 0.0001) and 5-HIAA (F,,,, = 106, p < O.OOOl), as reported previously (Sanders-Bush et al., 1972; Fuller and Snoddy, 1974) . Vehicle infusions into the cortex of PCA-lesioned rats (veWPCA) did not alter indoleamine levels when compared to the contralateral, noninfused cortex (Table 1 ; p 2 0.05). In contrast, intracortical infusions of BDNF in PCAlesioned animals (BDNF/PCA) attenuated the decline in 5-HT and 5-HIAA levels in the cortical area surrounding the infusion cannula [ Table 1 ; significant interaction between BDNF infusion and side of cortex for 5-HT (F,,z, = 14.2, p < 0.001) and 5-HIAA (F,,3, = 7.0, p < O.OS)]. The BDNF/PCA animals showed eightfold and threefold increases in 5-HT and 5-HIAA levels, respectively, in the BDNF infused cortex relative to the contralateral cortex [ Fig. 6 ; two-factor ANOVA on indolamine levels in the infused/contralateral cortex for each animal; for 5-HT PCA treatment (F,,z, = 11.6, p < O.OOS), BDNF infusion (F,.za = 10.6, p < O.OOS), interaction between PCA treatment and BDNF infusion (F,,28 = 8.2, p < 0.01); for 5-HIAA: PCA treatment (F,,,, = 6.8, p < O.OS), BDNF infusion (F,,s, = 7.9, p < O.Ol)]. Post hoc Newman-Keuls comparisons showed that, for both 5-HT and 5-HIAA measures, the BDNF/PCA group differed significantly from the three other groups 0, < 0.05), while none of the other group differences reached statistical significance (Fig. 6) . No significant changes were found in the 5-HT/S-HIAA ratio for any of the groups. High afinity jH-5-HT uptake. Three-week intracortical infusions of vehicle did not alter high affinity 3H-5-HT uptake in the intact cortex: vehlveh animals showed similar accumulations of 3H-5-HT in the infused (right) and contralateral (left) frontoparietal cortices (Table 1 ; three-factor repeated measures ANOVA, followed by the Newman-Keuls multiple range test, p 2 0.05). Systemic administration of PCA caused a significant reduction in cortical 3H-5-HT uptake (Table 1 ; main effect of PCA treatment: F,,,, = 122, p < 0.0001). 3H-5-HT uptake in the infused and contralateral cortices of veh./PCA animals was decreased by 63% and 66%, respectively, from the values found in control (vehlveh) animals. Vehicle infusions into the cortex of PCA-lesioned rats (veWPCA) did not alter 3H-5-HT uptake when compared to the contralateral cortex (Table 1 ; p 2 0.05). However, intracortical infusions of BDNF in PCA-treated animals (BDNF/PCA) increased 3H-5-HT uptake by twofold relative to the contralateral cortex, thus attenuating the loss of 5-HT uptake normally caused by PCA [ Table 1 , Fig. 6 ; two-factor ANOVA on 3H-5-HT uptake in the infused/contralateral cortex for each animal: PCA treatment (F,,,, = 8.0, p < O.Ol), interaction between PCA treatment and BDNF infusion (F,,,, = 5.1, p < O.OS)]. Post hoc Newman-Keuls comparisons showed that the BDNF/PCA group differed significantly from the three other groups 0, < O.OS), while none of the other group differences reached statistical significance (Fig. 6 ).
The effects of BDNF on 5-HT uptake in vitro Since 5-HT uptake inhibitors such as fluoxetine or citalopram can prevent the PCA-induced degeneration of serotonergic axons in vivo (reviewed by Fuller and Henderson, 1994) , we evaluated the in vitro effects of BDNF on "H-5-HT uptake in rat Figure 4 . The morphology of serotonergic axons exposed to BDNE In addition to the higher fiber density, the BDNF-exposed 5-HT axons in both PCA-lesioned (BDNFPCA) and intact (BDNFheh) rats appear to be slightly thicker, more intensely immunoreactive and more convoluted than those in the homologous cortex of control (W/Z/V&) rats. Bright-field photomicrographs; note that the top two photographs are at a lower magnification than the bottom pair of photographs: scale bars for each pair, 10 ym. cortical homogenates to determine whether BDNF was also acting through inhibition of the 5-HT uptake carrier. BDNF, in concentrations ranging from 20 PM to 2 p,M, did not inhibit the uptake of 3H-5-HT into cortical homogenates (Controls: 155 t 14 fmol/mg tissue vs 2 FM BDNF: 151 2 13 fmol/mg tissue; F 6.23 = 0.79, NS). NT-3, in concentrations of 0.5 and 2 FM, also did not inhibit the uptake of 3H-5-HT into cortical homogenates (Controls: 122 ? 13 fmoVmg tissue vs 2 PM NT-3: 106 ? 25 fmol/mg tissue; Fz,,, = 0.38, NS).
Discussion
Serotonergic axons are normally found in high density throughout neocortex and other forebrain areas of the adult rat (Blue et al., 1988; Mamounas et al., 1991) . Systemic administration of the amphetamine analog PCA causes a rapid degeneration of most 5-HT axons in forebrain, leading to a severe and longlasting denervation of cortex (Fuller and Snoddy, 1974; SandersBush et al., 1972; Mamounas et al., 1991 Mamounas et al., , 1992 . Using immunocytochemical and neurochemical methods, the present study has shown that continuous 3 week infusions of BDNF directly into the rat frontoparietal neocortex elicits a local sprouting response from uninjured serotonergic axons in the nonlesioned cortex and completely prevents the PCA-induced degenerative loss of 5-HT axons in the cortical area near the BDNF infusion cannula. This protective effect upon serotonergic axons is selec- Figure 5 . Correspondence between the distribution of spared 5-HT axons surrounding the BDNF infusion cannula in a BDNF/PCA animal (top; dark-field photomicrograph) and the area of diffusion of exogenously delivered BDNF as determined by BDNF immunocytochemistry in an adjacent section (bottom; bright-field photomicrograph). The 5HT axon density is highest along the perimeter of the area of BDNF diffusion. Note also the spread of the infused BDNF along the pial surface of cortex in this particular case, which is likewise associated with a high density of 5-HT axons at this location. Scale bar, 250 pm.
tive for BDNF since NT-3 caused only a partial sparing of the 5-HT innervation in PCA-treated rats, whereas infusions of vehicle, cytochrome c, or NGF failed to prevent the PCA-induced loss of 5-HT axon density. Thus, BDNF is the first endogenous, neuronal-derived brain compound that has been shown to promote the survival or sprouting of serotonergic axons in the brain.
An important question that arises is whether BDNF prevents the PCA-induced loss of 5-HT axon density by rescuing serotonergic axons from degeneration, or by restoring the content of 5-HT back to detectable'levels within otherwise structurally intact axons. One way of answering this question is by understanding the neurotoxic actions of PCA, itself. The ring-substituted amphetamines, including PCA, MDA, MDMA, and fenfluramine, belong to a class of compounds that cause, within hours, the release of 5-HT from nerve terminals followed by a prolonged depletion of brain 5-HT content (reviewed by Fuller and Henderson, 1994) . Considerable evidence indicates that this long-term depletion of 5-HT results from the structural deterioration of 5-HT axons, as opposed to a reduction of 5-HT content within intact axons (reviewed by Axt et al., 1994) . Within 2-3 d after PCA administration, extremely enlarged, fragmented 5-HT-and tryptophan hydroxylase-immunoreactive axon terminals are found in cortex, indicative of axonal degeneration (Axt et al., , 1994 . Silver impregnation studies reveal degenerating, argyrophilic axon terminals in striatum l-2 d after MDMA, MDA or PCA administration (Ricaurte et al., 1985; Commins et al., 1987) . Further evidence that these drugs cause axon degeneration is the presence of activated microglia (Wilson and Molliver, 1994) and astrocytes (Axt et al., 1994) in cortex between l-6 weeks after treatment with PCA. The acute cytopathic changes are accompanied by a marked and long-lasting loss of 5-HT and 5-HIAA levels, 5-HT-immunoreactive axon terminals, tryptophan hydroxylase activity, high-affinity 5-HT uptake and binding sites for the 5-HT transporter in the forebrain (Sanders-Bush et al., 1972 , 1975 Fuller and Snoddy, 1974; Ricaurte et al., 1985; Stone et al., 1987; Battaglia et al., 1988; Mamounas et al., 1991 Mamounas et al., , 1992 Scanzello et al., 1993) . These serotonergic deficits were shown to persist for at least 3-4 months and, in some studies, up to one year after drug treatment, thus strongly indicating 5-HT axon degeneration. In addition to the above parameters, retrograde and anterograde transport between terminal rich areas in cortex and 5-HT cell bodies in the raphe nuclei is nearly abolished at 3 d and for at least 6 weeks after PCA administration Haring et al., 1992; Axt et al., 1994) . Despite the persistent loss of 5-HT in forebrain terminal fields after treatment with PCA, MDA, or MDMA, the serotonergic cell bodies in the raphe nuclei and the proximal portions of 5-HT axons in the major fiber pathways do not degenerate and remain intensely 5-HT-immunoreactive O'Hearn et al. 1988; Axt et al., 1994) , arguing against a loss of serotonergic phenotype expression in these neurons. Thus, an extensive literature on PCA neurotoxicity indicates that the ability of BDNF to prevent the PCA-induced loss of 5-HT-immunoreactive axons most likely results from its ability to rescue serotonergic axons from degeneration or enhance their sprouting after damage, as opposed to restoring 5-HT transmitter expression within structurally intact axons. In the present study, the altered morphology and supranormal densities of BDNF-exposed 5-HT axons, and the attenuation of the PCA-induced loss of high-affinity "H-5-HT uptake further support the view that BDNF acts upon the structural characteristics of serotonergic axons rather than upregulating 5-HT content alone. There are two possible explanations for how BDNF may prevent the loss of serotonergic axon density that is normally seen 2 weeks after PCA administration. First, BDNF may prevent the PCA-induced degeneration of 5-HT axons. A second intriguing possibility is that the 5-HT axon terminals degenerate in the BDNF/PCA animals but then, in the presence of BDNR undergo a rapid and dramatically enhanced sprouting response during the 2 weeks after PCA administration. After chemical axotomy by PCA, endogenous sprouting of the damaged 5-HT axons in frontoparietal cortex does not begin until about l-2 months later and only partly restores the normal innervation density by 6 months (Mamounas et al., 1992; Axt et al., 1994) . In contrast to PCA, lesioning serotonergic fibers with the chemical neurotoxin 5,6-dihydroxytryptamine causes a rapid sprouting that begins within 1 week in some brain areas, and results in a terminal plexus of normal density by one month and a hyperinnervation at longer survival times (Wiklund and Bjbrklund, 1980) . Thus, under favorable conditions, serotonergic neurons can respond to injury by rapid and vigorous sprouting. The possibility that exogenous administration of BDNF facilitates the normally slow sprouting of PCA-damaged S-HT axons is supported by several findings from this study. First, BDNF infusions can induce a robust sprouting of uninjured serotonergic axons, as evidenced by the substantially increased density and altered morphology of BDNF-exposed 5-HT axons in the nonlesioned cortex (BDNF/ veh). It is unlikely that this apparent hyperinnervation and altered morphology of 5-HT axons simply reflects a BDNF-induced upregulation of 5-HT content in existing axons, thereby revealing previously undetected serotonergic axons. In earlier studies (Blue et al., 1988; Mamounas and Molliver, 1988; Mamounas et al., 1991) , monoamine oxidase (MAO) inhibitors were often used to enhance the intensity of 5-HT immunostaining by increasing the 5-HT content within axons; pretreatment with MAO inhibitors prior to fixation did not cause an apparent increase in the density or change in the morphology of serotonergic axons in intact or PCA-lesioned animals. Second, in the BDNF/PCA animals, intracortical infusions of BDNF did not simply rescind the PCA-induced loss of 5-HT axons but, in many cases, markedly increased the serotonergic innervation density above the normal levels found in control (veWveh) animals. Finally, the thicker and more convoluted morphology of the BDNF-exposed 5-HT axons in PCA-lesioned animals suggests that active sprouting mechanisms are invoked, as opposed to a sparing of existing axons. In current experiments, the temporal parameters of BDNF and PCA delivery are being manipulated to determine whether BDNF prevents the PCA-induced degeneration of serotonergic axons or dramatically facilitates and accelerates the sprouting of 5-HT axons after degeneration or both. We have preliminary evidence that 2 week infusions of BDNF started 4 d after PCA administration can markedly enhance the sprouting of prelesioned serotonergic axons (L. A. Mamounas, M. E. Blue, and C. A. Altar, unpublished observations) . Based on the findings from other neurodegeneration models, a tropic role for the neurotrophins in promoting axonal growth after injury has been proposed, in addition to their role in supporting neuronal survival (reviewed by Gage et al., 1990) . For example, after fimbria-fornix transection, exogenous administration of NGF causes sprouting of local cholinergic axons in the lateral septum (Williams et al., 1986) and promotes the regrowth of lesioned septal cholinergic fibers across a "grafting bridge" into the hippocampus (Hagg et al., 1990; Tuszynski et al., 1990) . In addition to its effects upon axotomized neurons, NGF can elicit the sprouting of mature, uninjured sympathetic axons (Isaacson et al., 1992) and promote neurite growth from nonlesioned cholinergic neurons in the adult brain (Koliatsos et al., 1991; Tuszynski et al., 1991) . Similarly, BDNF infusions in the present study elicited a robust sprouting of uninjured serotonergic axons in intact animals, thus supporting the proposal by Isaacson et al. (1992) that mature neuronal connections are continually being remodeled by tropic interactions. Interestingly, an endogenous hyperinnervation by serotonergic axons is observed in primary sensory cortex during neonatal development (D'Amato et al., 1987) , similar to that seen in the BDNF-ipfused cortex of the adult. Further experiments are needed to determine whether this serotonergic hyperinnervation during development as well as the endogenous sprouting of 5-HT axons after PCA or 5,6-dihydroxytryptamine are associated with the increased expression of BDNF or its receptor in the brain.
The size of the cortical area protected from serotonergic denervation by the BDNF infusion (about 3 mm in diameter) is virtually identical to the area of diffusion of BDNF as determined by immunocytochemistry in an adjacent section (Fig. 5) . Interestingly, in both the PCA-lesioned and intact rats, there was Figure 6 . Levels of 5-HT (top histogram) and 5-HIAA (middle) and high affinity IH-5-HT uptake (bottom), expressed as the ratio of the neurochemical value in the infused (right) cortex relative to the contralateral (noninfused) cortex for each animal (see Table 1 for absolute values). The data were analyzed with a 2 X 2 (PCA treatment X BDNF infusion) ANOVA, followed by the Newman-Keuls multiple range test. For each neurochemical evaluation, the BDNFIPCA group differed significantly from the three other groups, while none of the other group differences reached statistical significance; *, p < 0.05.
often a striking annulus of higher 5-HT axon density beginning about 0.5-l mm from the BDNF infusion cannula (Fig. 2) . This localized area of 5-HT hyperinnervation could represent an optimal concentration of BDNF for effects on 5HT axons or could result from glial or other reactions closer to the cannula tip that are less favorable to 5-HT axon growth. The neurochemical evaluations in this study supported the immunocytochemical data, but were less sensitive in detecting the effects of BDNF on 5-HT axons. Using neurochemistry, the BDNF infusions in PCA-lesioned animals yielded only a partial recovery of 5-HT and 5-HIAA levels and high affinity 'H-5-HT uptake, and these measures were not significantly elevated in the BDNF infused cortex of intact animals (Table 1) . Thus, the BDNF-induced 5-HT hyperinnervation observed with immunocytochemistry is not fully reflected in the neurochemical measures. This reduced apparent effect with the neurochemical procedures most likely results from the discrete localization of higher 5-HT axon density within a narrow annulus (0.5-l mm wide), thereby including lesser affected tissue within the 3 mm diameter punch surrounding the cannula site.
Among the neurotrophins examined in this study, the selectivity of BDNF in preventing the PCA-induced loss of 5-HT axons suggests that BDNF is acting via pharmacologically specific neurotrophin receptors in brain and supports the concept that the different neurotrophins activate distinct but overlapping neuronal populations. Consistent with our results that NGF was not neurotrophic for cortical 5-HT axons are the findings that NGF fails to elicit 5-HT neurite outgrowth in embryonic raphe cultures , or cause serotonergic axon sprouting in the adult rat striatum (Kawaja and Gage, 1991) , despite its ability to promote robust sprouting of cholinergic (Williams et al., 1986; Kawaja and Gage, 1991) and sympathetic (Isaacson et al., 1992) fibers. Moreover, NT-3, in this study, was considerably less potent than BDNF in promoting the survival of serotonergic axons after PCA, which remarkably parallels the relative potencies of these neurotrophins in augmenting 5-HT metabolism and analgesia (Siuciak et al., 1994) . NGF and BDNF activate high affinity TrkA and TrkB receptors, respectively, while NT-3 preferentially activates TrkC and less potently stimulates the TrkB receptor (Kaplan et al., 1991; Lamballe et al., 1991; Squint0 et al., 1991) . Thus, our findings suggest that the TrkB receptor mediates the neurotrophic effects of BDNF on serotonergic neurons. The cellular mechanisms responsible for the survival promoting actions of BDNF on 5-HT axons are not known. It is well established that inhibitors of the 5-HT transporter can completely block the PCA-induced degeneration of 5-HT axons (Fuller and Henderson, 1994) . However, our results suggest that BDNF is not mediating its protective effects on 5-HT axons by inhibiting the 5-HT uptake carrier, since BDNF failed to inhibit the in vitro uptake of 'H-5-HT into cortical homogenates. Since the neurotrophins have been shown to increase catalase and glutathione reductase activity (Jackson et al., 1990; Spina et al., 1992) and PCA neurotoxicity may be mediated by oxidative mechanisms (Steranka and Rhind, 1987; Stone et al., 1989 ) one intriguing possibility is that BDNF may protect serotonergic axons from PCA-induced damage by augmenting oxidative stress protective mechanisms.
The protective effects of BDNF on neurotoxin damaged 5-HT axons suggests that BDNF may have a physiologic roPe in regulating the survival of serotonergic neurons in the adult brain and may prove useful as a therapeutic agent in ameliorating the serotonergic loss that occurs during aging or disease. Further evidence supporting a physiological role of BDNF for serotonergic neurons are the presence of BDNF displaceable binding sites and trkB mRNA (Merlio et al., 1992) in the dorsal raphe nucleus, the retrograde transport of BDNF from 5-HT terminal fields in cortex to cell bodies in the raphe nuclei (Anderson et al., 1995) and the in viva regulation of serotonergic metabolism and function by BDNF Martin-Iverson et al., 1994; Siuciak et al., 1994) . Thus, exogenous BDNF appears to be capable of augmenting functional as well as structural aspects of serotonergic neurons. The ability of BDNF to induce the sprouting of intact serotonergic fibers and prevent the PCA-induced loss of 5HT axons is of particular interest, inasmuch as BDNF mRNA levels are particularly abundant in the neocortex (Ernfors et al., 1990) . Thus, cortical BDNF levels or trkB receptor activation may regulate the individual susceptibility of serotonergic axons to 5HT neurotoxins such as PCA, MDA, MDMA, and fenfluramine. Moreover, the marked serotonergic pathology observed during aging (van Luijtelaar et al., 1992) or in Alzheimer's disease (Cross, 1990) could be due to decrements in local BDNF availability (Phillips et al., 1991) . Therapeutic interventions that augment BDNF levels or its signal transduction pathways may prove useful during aging or in neurodegenerative disease by promoting the survival of serotonergic neurons or by inducing the compensatory sprouting of residual 5-HT axon terminals.
